2. Academic Validation
  3. Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study

Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study

  • J Clin Oncol. 2024 Jul 1;42(19):2281-2294. doi: 10.1200/JCO.23.01909.
Aditya Bardia 1,  Ian E Krop 2 3,  Takahiro Kogawa 4,  Dejan Juric 1,  Anthony W Tolcher 5 6 7,  Erika P Hamilton 8 9,  Toru Mukohara 10,  Aaron Lisberg 11,  Toshio Shimizu 12 13,  Alexander I Spira 14,  Junji Tsurutani 15,  Senthil Damodaran 16,  Kyriakos P Papadopoulos 17,  Jonathan Greenberg 18 19,  Fumiaki Kobayashi 20,  Hong Zebger-Gong 19,  Rie Wong 21,  Yui Kawasaki 18,  Tadakatsu Nakamura 20,  Funda Meric-Bernstam 16
Affiliations

Affiliations

  • 1 Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.
  • 2 Yale Cancer Center, New Haven, CT.
  • 3 Dana-Farber Cancer Institute, Boston, MA.
  • 4 Department of Advanced Medical Development, Cancer Institute Hospital of JFCR, Tokyo, Japan.
  • 5 South Texas Accelerated Research Therapeutics, San Antonio, TX.
  • 6 NEXT Oncology, San Antonio, TX.
  • 7 Texas Oncology, San Antonio, TX.
  • 8 Sarah Cannon Research Institute, Nashville, TN.
  • 9 Tennessee Oncology, PLLC, Nashville, TN.
  • 10 Department of Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
  • 11 Department of Medicine, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA.
  • 12 Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan.
  • 13 Department of Pulmonary Medicine and Medical Oncology, Wakayama Medical University Hospital, Wakayama, Japan.
  • 14 Virginia Cancer Specialists (VCS) Research Institute, Fairfax, VA.
  • 15 Advanced Cancer Translational Research Institute, Showa University, Tokyo, Japan.
  • 16 Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • 17 Clinical Research, START, San Antonio, TX.
  • 18 Global Oncology Clinical Development, Daiichi Sankyo, Inc, Basking Ridge, NJ.
  • 19 Global Oncology Clinical Development, Daiichi Sankyo Europe GmbH, Munich, Germany.
  • 20 Data Intelligence, Daiichi Sankyo, Co, Ltd, Tokyo, Japan.
  • 21 Global Oncology Clinical Development, Daiichi Sankyo, Co, Ltd, Tokyo, Japan.
PMID: 38652877 DOI: 10.1200/JCO.23.01909
Abstract

Purpose: Datopotamab deruxtecan (Dato-DXd) is an antibody-drug conjugate consisting of a humanized antitrophoblast cell-surface antigen 2 (TROP2) monoclonal antibody linked to a potent, exatecan-derived Topoisomerase I inhibitor payload via a plasma-stable, selectively Cleavable Linker.

Patients and methods: TROPION-PanTumor01 (ClinicalTrials.gov identifier: NCT03401385) is a phase I, dose-escalation, and dose-expansion study evaluating Dato-DXd in patients with previously treated solid tumors. The primary study objective was to assess the safety and tolerability of Dato-DXd. Secondary objectives included evaluation of antitumor activity and pharmacokinetics. Results from patients with advanced/metastatic hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) breast Cancer (BC) or triple-negative BC (TNBC) are reported.

Results: At data cutoff (July 22, 2022), 85 patients (HR+/HER2- BC = 41, and TNBC = 44) had received Dato-DXd. The objective response rate by blinded independent central review was 26.8% (95% CI, 14.2 to 42.9) and 31.8% (95% CI, 18.6 to 47.6) for patients with HR+/HER2- BC and TNBC, respectively. The median duration of response was not evaluable in the HR+/HER2- BC cohort and 16.8 months in the TNBC cohort. The median progression-free survival in patients with HR+/HER2- BC and TNBC was 8.3 and 4.4 months, respectively. All-cause treatment-emergent adverse events (TEAEs; any grade, grade ≥3) were observed in 100% and 41.5% of patients with HR+/HER2- BC and 100% and 52.3% of patients with TNBC. Stomatitis was the most common TEAE (any grade, grade ≥3) in both HR+/HER2- BC (82.9%, 9.8%) and TNBC (72.7%, 11.4%) cohorts.

Conclusion: In patients with heavily pretreated advanced HR+/HER2- BC and TNBC, Dato-DXd demonstrated promising clinical activity and a manageable safety profile. Dato-DXd is currently being evaluated in phase III studies.

Figures
Products